Anemia in Peritoneal Dialysis Patients; Iron Repletion, Current and Future Therapies

Zeidan, Ahmed; Bhandari, Sunil

doi:10.3747/pdi.2016.00193

Cited by 15 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is extensive clinical trial evidence supporting the efficacy of IV iron preparations in patients with both non-dialysis-dependent and end-stage CKD [ 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 ] and patients with CHF [ 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 ], IBD [ 28 , 111 , 112 , 113 , 114 , 115 , 116 , …”

Section: Clinical Use Of IV Ironmentioning

confidence: 99%

Intravenous Irons: From Basic Science to Clinical Practice

et al. 2018

Self Cite

View full text Add to dashboard Cite

Iron is an essential trace mineral necessary for life, and iron deficiency anaemia (IDA) is one of the most common haematological problems worldwide, affecting a sixth of the global population. Principally linked to poverty, malnutrition and infection in developing countries, in Western countries the pathophysiology of IDA is primarily linked to blood loss, malabsorption and chronic disease. Oral iron replacement therapy is a simple, inexpensive treatment, but is limited by gastrointestinal side effects that are not inconsequential to some patients and are of minimal efficacy in others. Third generation intravenous (IV) iron therapies allow rapid and complete replacement dosing without the toxicity issues inherent with older iron preparations. Their characteristic, strongly-bound iron-carbohydrate complexes exist as colloidal suspensions of iron oxide nanoparticles with a polynuclear Fe(III)-oxyhydroxide/oxide core surrounded by a carbohydrate ligand. The physicochemical differences between the IV irons include mineral composition, crystalline structure, conformation, size and molecular weight, but the most important difference is the carbohydrate ligand, which influences complex stability, iron release and immunogenicity, and which is a unique feature of each drug. Recent studies have highlighted different adverse event profiles associated with third-generation IV irons that reflect their different structures. The increasing clinical evidence base has allayed safety concerns linked to older IV irons and widened their clinical use. This review considers the properties of the different IV irons, and how differences might impact current and future clinical practice.

show abstract

Section: Clinical Use Of IV Ironmentioning

confidence: 99%

Intravenous Irons: From Basic Science to Clinical Practice

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…While uremic toxins worsen anemia parameters in CKD, there was no correlation between dialysis and IS, IAA, or PCS (Bataille et al, 2017). There is scant information on anemia and the treatment of anemia in PD patients [ 29 ]. The prevalence of anemia remains high after RT at approximately 36–40% [ 30 , 31 ] and is associated with increased mortality [ 31 , 32 ].…”

Section: Introductionmentioning

confidence: 99%

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Chou

Kiebalo

Jagiello

et al. 2021

Life

View full text Add to dashboard Cite

Patient survival continues to increase with the growing quality of dialysis and management of chronic kidney disease (CKD). As such, chronic therapy must include considerations of quality of life (QOL), and this includes the disproportionate prevalence of sexual dysfunction (SD) in this patient population. This review aims to describe the pathophysiological and the psychosocial causes of SD with regard to renal replacement therapy, particularly hemo- and peritoneal dialysis. The differences in its manifestation in men and women are compared, including hormonal imbalances—and therefore fertility, libido, and sexual satisfaction—the experience of depression and anxiety, and QOL. The impact of comorbidities and the iatrogenic causes of SD are described. This review also presents validated scales for screening and diagnosis of SD in CKD patients and outlines novel therapies and strategies for the effective management of SD. Increased prevalence of CKD invariably increases the number of patients with SD, and it is crucial for health care professional teams to become familiar with the clinical tools used to manage this sensitive and under-quantified field. As a known predictor of QOL, sexual function should become a point of focus in the pursuit of patient-centered care, particularly as we seek to achieve as “normal” a life as possible for individuals who receive dialysis.

show abstract

“…and is related to a higher incidence of cardiovascular disease, mortality, and morbidity along with the poorer quality of life and prognosis (3). Based on evidence of the improvement of the anemia status of 50-70% of patients with CKD (4), the current recommendation for clinical management of anemia in CKD is erythropoietic stimulants combined with iron supplements (5,6).…”

mentioning

confidence: 99%

Effectiveness and safety of roxadustat in the treatment of anemia of kidney disease: a systematic review and meta-analysis

Wang¹,

Wang²,

Chen³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Chronic kidney disease is a global public health problem, anemia is the most common complication of chronic kidney disease. Roxadustat is a new drug that can be used to treat renal anemia by oral administration.Methods: We conducted a comprehensive computerized search of the China Knowledge Network (CNKI), VIP (VIP), Wanfang, China Biomedical (CBM), PubMed, Embase, and the Cochrane Library databases. We collected clinical randomized controlled trials (RCTs) published on roxadustat in the treatment of anemia of kidney disease. According to the inclusion and exclusion criteria, the included studies were subject to screening and quality evaluation, and RevMan 5.3 software was used for meta-analysis.Results: A total of 7 RCTs involving 997 patients with anemia of kidney disease were included. The results of meta-analysis showed that compared with the treatment effect of the erythropoietin (EPO) group, in the roxadustat group there were significant increases in the amount of hemoglobin [mean difference (MD) =11.70, 95% confidence interval (CI): 0.41 to 22.99, P=0.04], hemoglobin overall response rate [odds ratio (OR) =1.

show abstract

Anemia in Peritoneal Dialysis Patients; Iron Repletion, Current and Future Therapies

Cited by 15 publications

References 46 publications

Intravenous Irons: From Basic Science to Clinical Practice

Intravenous Irons: From Basic Science to Clinical Practice

Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

Effectiveness and safety of roxadustat in the treatment of anemia of kidney disease: a systematic review and meta-analysis

Contact Info

Product

Resources

About